In a subgroup of high-risk asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events

In a subgroup of high-risk asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events

Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/ day) in reducing cardiovascular events. Clinicians in Asia doubt...

Full description

Bibliographic Details
Published in:PLoS ONE
Main Author: Dans A.L.; Teo K.; Gao P.; Chen J.-H.; Jae-Hyung K.; Yusoff K.; Chaithiraphan S.; Zhu J.; Lisheng L.; Yusuf S.
Format: Article
Language:English
Published: 2010
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650969240&doi=10.1371%2fjournal.pone.0013694&partnerID=40&md5=7ad888439ab40ca8371492005fdb0613

Internet

https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650969240&doi=10.1371%2fjournal.pone.0013694&partnerID=40&md5=7ad888439ab40ca8371492005fdb0613

Similar Items